Gotcha. It seems clear from the last press release that the company is utterly focused on Bril-OM and partnerships now. When there is partnership money, they can get Kevetrin stuff going again. I'm glad that they are focused on the Bril-OM pathway towards approval. Having a drug complete Phase 3 will make a huge difference -- especially when we know it's practically a slam-dunk, given the great results from the earlier clinical trials.